DNA Ginkgo Bioworks Holdings, Inc. Class A

Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.

$8.65  -1.57 (-15.36%)
As of 12/03/2021 16:00:02 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  04/19/2021
Outstanding shares:  1,310,783,159
Average volume:  6,036,542
Market cap:   $13,396,203,885
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    37611X100
ISIN:        
Sedol:      BN6KXF0
Valuation   (See tab for details)
PE ratio:   -48.31
PB ratio:   8.29
PS ratio:   74.99
Return on equity:   -14.15%
Net income %:   -128.15%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy